Cantor Fitzgerald reaffirmed their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $58.00 price target on the biopharmaceutical company’s stock. XENE has been the topic of several other research reports. Stifel Nicolaus lifted their price target […]
Xenon Pharmaceuticals (NASDAQ:XENE) Now Covered by Analysts at StockNews.com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Pictet Asset Management SA Sells 115,322 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Xenon Pharmaceuticals (XENE) Set to Announce Quarterly Earnings on Wednesday theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Eversept Partners LP grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 275,704 shares of the biopharmaceutical company’s stock after purchasing an additional 16,092 shares during […]